Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer-Reference-Cited by-同舟云学术

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

Published:2017-01 Issue:3 Volume:116 Page:318-323
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Marmorino Federica,Salvatore Lisa,Barbara Cecilia,Allegrini Giacomo,Antonuzzo Lorenzo,Masi Gianluca,Loupakis Fotios,Borelli Beatrice,Chiara Silvana,Banzi Maria Chiara,Miraglio Emanuela,Amoroso Domenico,Dargenio Francesco,Bonetti Andrea,Martignetti Angelo,Paris Myriam,Tomcikova Daniela,Boni Luca,Falcone Alfredo,Cremolini Chiara

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2016413.pdf

Reference23 articles.

1. Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, Sherod A, Iqbal S, El-Khoueiry A, Yang D, Zhang W, Danenberg PV, Lenz HJ (2007) Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics 8 (12): 1705–1713.

2. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S ML18147 Study Investigators (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14 (1): 29–37.

3. Contal C, O’Quigley J (1999) An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 30 (3): 253–270.

4. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd Eastern Cooperative Oncology Group Study E3200 (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (12): 1539–1544.

5. Granchi C, Bertini S, Macchia M, Minutolo F (2010) Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 17 (7): 672–697.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer;Digestive and Liver Disease;2024-08

2. The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer;Clinical and Translational Oncology;2024-06-21

3. Serum LDH and α-HBDH levels as biomarkers predicting the staging in lung adenocarcinoma patients;2024-05-15

4. Predicting COVID-19 outcomes in patients at advanced stages of HIV infection: a model-based approach;Epidemiology and Infectious Diseases;2024-03-06

5. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?;Expert Opinion on Pharmacotherapy;2024-03-03